Treatment at high-volume facilities is associated with improved overall survival for patients with cutaneous B-cell lymphoma

Abstract

To the Editor: Primary cutaneous B-cell lymphoma (CBCL), which comprises approximately 25% of cutaneous lymphomas, is much less common than cutaneous T-cell lymphoma. CBCLs require careful clinicopathologic correlation for accurate diagnosis and can range from more indolent (marginal zone lymphoma and follicle center lymphoma) to more aggressive (eg, diffuse large B-cell lymphoma) subtypes. Given the rarity and heterogeneity of CBCL, there is limited high-level data to guide management, with cases typically treated using a multidisciplinary approach using expert opinion and data from observational studies.